The University of Missouri and MU Health Care recently started a first round of in-person trials of a new cancer treatment.
Columbia Daily Tribune on MSN
Mizzou launches first trial of campus-made therapy for liver tumors
MU has launched its first clinical trial using reactor-made Eye90 microspheres to target inoperable liver tumors with precision radiotherapy.
HALIFAX, NS, Oct. 14, 2025 /PRNewswire/ - ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical ...
HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic ...
Funding supports Eye90 microspheres® FDA IDE approval toward U.S. pivotal study execution and ongoing clinical operations. HALIFAX, NS, Dec. 6, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative ...
In a major leap for cancer care at the University of Missouri, the School of Medicine and MU Health Care have launched their ...
HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic ...
HALIFAX, NS, April 19, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable ...
HALIFAX, Nova Scotia, April 8, 2019 /CNW/ -- ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results